Scotiabank raises target for Amgen stock from USD 450.00 to USD 500.00
Published on 10/05/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock (ISIN US0311621009) was trading at EUR 358.95 at Lang & Schwarz on October 5, 2026 at 9:09 a.m. CEST, plus 0.09 percent versus the prior close of EUR 358.63 on October 2, 2026. The latest analyst move came from Scotiabank, which raised its target from USD 450.00 to USD 500.00 on September 29, 2026, according to aktiencheck.de.
Scotiabank sets a USD 500.00 target
Analyst Louise Chen kept an outperform rating while lifting the target by USD 50.00, or 11.11 percent from USD 450.00. The USD 500.00 target lies 39.29 percent above the Lang & Schwarz euro price only if currencies are converted, so the two prices are kept separate rather than combined in one return calculation.
The target revision followed a run of pipeline and operating updates. Its timing matters because the company entered the autumn with the stock below its USD 447.03 52-week high on the Nasdaq, while the latest finance quote put market capitalization at USD 217.5 billion as of October 2, 2026.
Second-quarter revenue beats expectations
MarketBeat reported that Amgen generated USD 10.05 billion of revenue in the second quarter of 2026, versus a USD 9.43 billion consensus estimate. Revenue therefore exceeded consensus by USD 620.0 million, or 6.58 percent, while the reported year-over-year increase was 9.50 percent.
The same report said adjusted earnings per share reached USD 6.29 against a USD 5.62 consensus estimate. Amgen also declared a quarterly dividend of USD 2.52 per share, giving the stock a 2.50 percent yield in the cited market summary.
Dazodalibep adds pipeline evidence
On September 22, 2026, Amgen announced that the Phase 3 OASIZ 301 study of dazodalibep met its primary endpoint in adults with moderate-to-severe systemic Sjogren's disease. The company said improvement in disease activity was statistically significant and clinically meaningful at Week 48, with improvement observed as early as Week 4.
Amgen plans to present detailed OASIZ 301 data at a medical meeting, while the Phase 3 OASIZ 303 study is expected to complete in the fourth quarter of 2026. That timeline gives investors a defined clinical milestone, but the program still depends on further data, regulatory review and eventual commercialization.
Stock remains below the yearly high
On the Nasdaq, Amgen was last at USD 403.04 on October 2, 2026 at 4:00 p.m. ET, against a USD 288.00 to USD 447.03 52-week range. The Lang & Schwarz quote remained nearly unchanged against its prior close, leaving the Scotiabank target and the clinical pipeline as the more important reference points for the stock's valuation discussion.
The further course of trading is shown by the continuously updated real-time quote of Amgen stock.
Amgen market snapshot
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 5, 2026, 9:09 a.m. CEST): EUR 358.95
- Change versus prior close: plus 0.09 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 358.63
- Market capitalization: USD 217.5 billion (as of October 2, 2026)
- 52-week range: USD 288.00-447.03 (as of October 2, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Dow Jones Industrial Average and Nasdaq-100
